Enliven Therapeutics, Inc.
ELVN
$20.32
$0.3751.88%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 4.34% | 10.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.81% | 17.84% | |||
| Operating Income | 9.81% | -17.84% | |||
| Income Before Tax | 11.24% | -23.14% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 11.24% | -23.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 11.24% | -23.14% | |||
| EBIT | 9.81% | -17.84% | |||
| EBITDA | 9.85% | -17.91% | |||
| EPS Basic | 14.75% | -22.67% | |||
| Normalized Basic EPS | 14.73% | -18.21% | |||
| EPS Diluted | 14.75% | -22.67% | |||
| Normalized Diluted EPS | 14.73% | -18.21% | |||
| Average Basic Shares Outstanding | 4.10% | 0.39% | |||
| Average Diluted Shares Outstanding | 4.10% | 0.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||